“Multi-targeted tyrosine kinase inhibitor sorafenib. Application experience in kidney cancer with lung metastases”, Вопр. онкол., vol. 62, no. 1, pp. 154–156, Dec. 2016, doi: 10.37469/0507-3758-2016-62-1-154-156.